FENNEC PHARMACEUTICALS INC.: Sonic Fund II, L.P. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Sonic Fund II, L.P. filed an amended Schedule 13G with the SEC (accession 0001013594-26-001189) updating its beneficial ownership stake in Fennec Pharmaceuticals Inc. The filing, made under the 13G regime reserved for passive investors, revises the fund's previously reported position in the oncology-focused biopharmaceutical company. The amendment signals a change in Sonic Fund II's holdings, though the filing summary did not disclose the revised share count or percentage. Investors should watch for the full filing details to determine whether the fund increased or reduced its position, and whether the change crosses the 5% threshold that triggers heightened disclosure obligations.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Fennec Pharmaceuticals Inc., Sonic Fund II, L.P.